CardioBBEAT - Randomized Controled Trial to Evaluate the Health Economic Impact of Remote Patient Monitoring

Inclusion Criteria: * Confirmed diagnosis of Chronic Heart Failure (CHF) based on European Society of Cardiology (ESC) guidelines * Symptoms corresponding to New York Heart Association (NYHA) functional class II-IV * Left Ventricular Ejection Fraction (LVEF) ≤ 40% * American Heart Association (AHA) classification stage C or D * Age \> 18 years * Discharged after hospitalisation for worsening Chronic Heart Failure (CHF) within the last twelve months * Able to understand the German language * Sufficient eyesight to understand and follow the instructions communicated by the Motiva® platform * Willing and able to use the required hard- and software and maintain a patient diary * Residing within geographical reach of one of the ten study sites in order to receive additional treatment if required as well as follow-up consultation * Willingness to provide informed consent regarding benefits and risks related to the trial, and to sign a participation agreement for the installation of the telemedicine platform Motiva® Exclusion Criteria: * Myocardial infarction within the past four weeks * Heart surgery or any coronary intervention within the past eight weeks * Cardiogenic shock within the past four weeks * Intended cardiac surgery within the next six months or priority status on a waiting list for organ transplantation * Severe chronic and pulmonary illness with an immediate impact on the main outcome measures * Renal failure requiring dialysis * Dementia or other severe cognitive impairment * Psychiatric disorders rendering patients unable to participate in the trial * Discharged to or living in a geriatric clinic or a nursing home * Participation in another clinical trial